Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance

Samsung Bioepis Holdings and Samsung Biologics to Start Trading on 24 November

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> maintained positive momentum in 2Q25, with consolidated revenue and operating profit rising 11% and 9%, YoY, respectively. </li>
<li>Leveraging on strong 2Q result and successful ramp-up of Plant 4 providing additional momentum, the company has revised annual revenue growth guidance upward to 25–30% YoY from 20–25%.</li>
<li>Going ahead, the company is planning to shed its biosimilars subsidiary, Samsung Bioepis, to “focus on strengthening its core capabilities as a pure-play CDMO.”</li>
</ul>



Samsung Biologics (207940 KS) maintained positive momentum in 2Q25, with consolidated revenue and operating profit rising 11% and 9%, YoY, respectively. 
Leveraging on strong 2Q result and successful ramp-up of Plant 4 providing additional momentum, the company has revised annual revenue growth guidance upward to 25–30% YoY from 20–25%.
Going ahead, the company is planning to shed its biosimilars subsidiary, Samsung Bioepis, to “focus on strengthening its core capabilities as a pure-play CDMO.”


Samsung Biologics (207940 KS): Bumps up Full Year Guidance Amid Strong 2Q Show and Plant 4 Ramp-Up